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CASE PRESENTATION

BACKGROUND

TEACHING POINTS

A 50 year-old Asian woman with no significant past medical history and no
history of alcohol use presented with four days of abdominal discomfort and
progressive distention. Her physical examination was remarkable for normal
vital signs and a distended, non-tender abdomen with a fluid wave but without
hepatosplenomegaly. Complete blood count and liver tests were normal.
Abdominal ultrasound revealed ascites and an echogenic liver consistent with
hepatic steatosis or cirrhosis, which was initially suspected. Viral hepatitis
studies, human immunodeficiency virus antibody, ceruloplasmin, antimitochondrial antibody, alpha-1 antitrypsin, anti-smith antibody and antinuclear
antibodies were negative. CA-125 was markedly elevated at 301 U/ml (normal
< 22). Transvaginal ultrasonography revealed normal ovaries. . Computerized
tomography of the abdomen and pelvis revealed stranding and infiltration
throughout the mesenteric fat and omentum and a moderate-to-large volume of
ascites. Ascitic fluid examination revealed 42,900 total nucleated cells/cu mm of
which 88 % were mononuclear cells, 5 % neutrophils and 7 % lymphocytes. Her
serum ascitic-albumin gradient was less than 1. Further analysis of ascitic fluid
showed abnormal B-cells expressing CD 19, CD 20, CD 10, FMC 7, and CD 45;
FISH analysis showed MYC/IgH fusion associated with translocation of t (8;14)
(q24;q32) characteristic of Burkitt lymphoma. Her serum LDH was 910 U/L
(normal 82 – 310). Serum uric acid was normal. Bone marrow biopsy and
lumbar puncture were both negative for Burkitt lymphoma involvement.
Aggressive hydration was started to prevent tumor lysis syndrome. She was
treated with HyperCVAD ( Cyclophosphamide, Vincristine, Doxorubicin and
dexamethasone alternating with high dose methotrexate and cytarabine +
rituximab). She tolerated this regimen well without neutropenia or any significant
side effects.

History. Burkitt lymphoma was first described in 1958 by Dennis Burkitt, an
Irish surgeon working in central Africa. He initially described a patient with what
he felt was a sarcoma but three years later, it was found to be a malignant
lymphoma. Burkitt lymphoma is defined by the World Health Organization as a
highly aggressive mature B cell neoplasm with several subtypes, all of which
share a genetic translocation of the c-myc gene, most commonly a t(8;14)
mutation.
Clinical manifestations. A sporadic form usually presents with extra nodal
disease, most commonly in the abdomen. Patients may present with nausea,
vomiting, diarrhea and even an acute abdomen-like picture which may be
mistaken for intussusception. Gastrointestinal bleeding may also be a
presenting feature. Bone marrow involvement is seen in 30-35% of the cases
and central nervous system involvement in 13-17% of adults. Occasionally,
patients may present with spontaneous tumor lysis syndrome. Presentation as
malignant ascites is rare. Unlike the sporadic form, the endemic form is
associated with Ebstein Barr virus and presents with jaw and renal involvement.
Interestingly, the immunodeficiency subtype presents among Human
Immunodeficiency Virus patients with CD4 count higher than 200.
Diagnosis. Diagnosis relies on histopathology showing monomorphic medium
sized cells with basophilic cytoplasm and a high proliferation fraction with Ki-67
fraction approaching 100 %. The classic “starry sky appearance" is due to the
abundant proliferative rate, frequent apoptosis and numerous macrophages
containing ingested apoptotic cells. Translocation of the c-myc gene on
chromosome 8 is a characteristic feature. The malignant cells express Ig M,
Bcl-6, CD19, CD20, CD22, CD10 and CD79a. Immunophenotyping and cell
surface analysis by flow cytometry are important steps in the diagnostic process.
Cytogenetic studies with FISH demonstrate the (8;14) translocation of the c-myc
gene, or bcl2; bcl6 gene rearrangements.
Treatment and prognosis. HyperCVAD or CODOXMIVAC(Cyclophosphamide, Doxorubicin and Vincristine with intra thecal
methotrexate and cytarabine followed by high dose methotrexate, +/Rituximab) are two of the commonly used regimens. CNS involvement being
very common, CNS prophylaxis is required for all patients and is accomplished
with high dose methotrexate, intra thecal chemotherapy or high dose
cytarabine. Autologous stem cell transplant is also being incorporated in some
of the treatment regimens. Treatment related mortality is as high as 8 %, with
the most common side effect being neutropenia. Advanced age, poor
performance status, CNS or bone marrow involvement are poor prognostic
factors. Failure to achieve a complete response within 4-6 weeks is also
predictive of a poor outcome. With the current treatments the response rate for
adults is as high as 65-100 %.

1. This woman presented with malignant ascites, the most common cause of
which is ovarian cancer. This was initially assumed to be the diagnosis
because of her elevated CA-125. CA-125 may be elevated in Burkitt
lymphoma.
2. The correct diagnosis was established by careful pathologic evaluation of
ascitic fluid, showing monomorphic medium sized cells with basophilic
cytoplasm and a high proliferation fraction with Ki-67 fraction approaching
100%.
3. Translocation of the c-myc gene on chromosome 8 is characteristic of
Burkitt’s lymphoma; this translocation is not unique to Burkitt lymphoma.
4. Burkitt lymphoma is rare, constituting less than 1% of B-cell lymphomas. It is
more common in males and usually presents with masses or tumor lysis
syndrome. Less commonly it may present with ascites. This form may have a
rapidly progressive course with bowel obstruction and/or gastrointestinal
bleeding.
5. We are aware of only one previous case of Burkitt lymphoma presenting with
ascites and an elevated CA-125.
6 . Burkitt lymphoma cells have a high growth fraction with a doubling time of 24
hours. Viable malignant cells may re-enter the cell cycle and grow rapidly
between chemotherapy cycles leading to development of resistance. Thus
there is urgency to initiate treatment.
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CONCLUSIONS
This case illustrates a rare cause of malignant lymphomatous ascites
masquerading as ovarian cancer. Careful cytologic analysis of ascitic fluid cells
led to the correct diagnosis.
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